Keywords: genentech, avastin, improves, survival, metastatic, colorectal, cancer

Genentech's Avastin improves survival in metastatic colorectal cancer

Article | 09 June 2003

Print This

At the American Society of Clinical Oncology annual meeting in Chicago, USA, Genentech presented positive Phase III data for Avastin ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in